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Background: The 20-meter walk test is a physical function measure commonly used in clinical research studies and
rehabilitation clinics to measure gait speed and monitor changes in patients’ physical function over time.
Unfortunately, the reliability and sensitivity of this walk test are not well defined and, therefore, limit our ability to
evaluate real changes in gait speed not attributable to normal variability. The aim of this study was to assess the
test-restest reliability and sensitivity of the 20-meter walk test, at a self-selected pace, among patients with mild to
moderate knee osteoarthritis (OA) and to suggest a standardized protocol for future test administration.
Methods: This was a measurement reliability study. Fifteen consecutive people enrolled in a randomized-controlled
trial of intra-articular corticosteroid injections for knee OA participated in this study. All participants completed 4
trials on 2 separate days, 7 to 21 days apart (8 trials total). Each day was divided into 2 sessions, which each
involved 2 walking trials. We compared walk times between trials with Wilcoxon signed-rank tests. Similar analyses
compared average walk times between sessions. To confirm these analyses, we also calculated Spearman
correlation coefficients to assess the relationship between sessions. Finally, smallest detectable differences (SDD)
were calculated to estimate the sensitivity of the 20-meter walk test.
Results: Wilcoxon signed-rank tests between trials within the same session demonstrated that trials in session 1
were significantly different and in the subsequent 3 sessions, the median differences between trials were not
significantly different. Therefore, the first session of each day was considered a practice session, and the SDD
between the second session of each day were calculated. SDD was −1.59 seconds (walking slower) and
0.15 seconds (walking faster).
Conclusions: Practice trials and a standardized protocol should be used in administration of the 20-meter walk test.
Changes in walk time between −1.59 seconds (walking slower) and 0.15 seconds (walking faster) should be
considered within the range of normal variability of 20-meter walking speed. The primary limitation of our study
was a small sample size, which may influence the generalizability of our findings.
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Osteoarthritis (OA) is a major debilitating disease affect-
ing more than 27 million individuals in the United States
[1], with numbers expected to rise as the obesity epidemic
continues to increase [2]. Knee OA is amongst the most
common and functionally limiting types of OA, causing* Correspondence: JMotyl@tuftsmedicalcenter.org
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reproduction in any medium, provided the orpain and functional impairment (e.g., slower gait speed)
[3,4]. In both clinical studies and rehabilitation clinics, it is
vital to have assessments that can monitor patients’ phys-
ical function over time.
Gait speed is an important functional outcome among
patients with knee OA. Physical therapy [5],exercise pro-
grams [6] and drug interventions [7] may improve gait
speed and can be easily assessed using 10-, 20-, or 50-
meter walk tests [8-14]. Unfortunately, each of these
short-distance walk tests may have different sensitivities.td. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
Motyl et al. BMC Musculoskeletal Disorders 2013, 14:166 Page 2 of 8
http://www.biomedcentral.com/1471-2474/14/166The 20-meter walk test is frequently used in clinical trials
and cohort studies involving individuals with OA, as well
as in physical therapy [15-22]. While a recent systematic
review [23] determined the 40-meter and 50-ft walk tests
have the best measurement evidence, this review did not
include the 20-meter walk test. Due to the 20-meter walk
test’s frequent use in OA studies, it is important to de-
termine its sensitivity and test-retest reliability using a
symptomatic population with mild to moderate OA, a
population often used in clinical trials for OA. There is
also a limited amount of literature regarding gait speed
changes over short periods of time (less than 30 days). Re-
search on changes in gait speed over short periods of time,
when no changes should have occurred, is important in
understanding what kind of change is attributed to real
change in gait speed versus a patient’s normal variability.
Smallest detectable differences (SDD) would allow both
clinicians and researchers to determine if a patient’s gait
speed is worsening or improving based on 20-meter walk
time. Therefore, the purpose of this study was to deter-
mine the test-retest reliability and sensitivity of the 20-
meter walk test at a self-selected pace among patients with
mild to moderate knee OA and to suggest a standardized
protocol for future 20-meter walk test administration in
both rehabilitation and research settings.
Methods
This study is reported according to the Guidelines for
Reporting Reliability and Agreement Studies (GRRAS)
[24].
Participants
The study sample included 15 consecutive participants
with mild to moderate knee OA attending screening (Day
1) and baseline (Day 2) visits between July 2011 and
December 2011 for a randomized-controlled trial of intra-
articular corticosteroid injections for knee OA (NIH
RO1AR057802-01, NCT01230424). All participants met
the American College of Rheumatology clinical criteria for
OA; had radiographic knee OA, as defined by Kellgren-
Lawrence grade 2 or 3 [25]; and knee synovitis, defined by
a synovial pouch depth greater than 2.0 mm measured by
ultrasound [26,27]. All participants were also required to
have knee pain symptoms, defined as a WOMAC Osteo-
arthritis Index (version 3.1, 5-point Likert) pain subscore ≥
2 at the beginning of the Day 1 visit. Symptoms were
reassessed at the beginning of the Day 2 visit, but this did
not influence eligibility. Participants were instructed to
withhold use of any non-steroidal anti-inflammatory med-
ications or analgesics within 48 hours of their study visits.
There were no other restrictions imposed. The Tufts Uni-
versity/Tufts Medical Center Institutional Review Board
approved this ancillary study, and informed consent was
collected prior to data collection.20-Meter walk (self-selected pace)
The 20-meter walk test was performed at two visits 8 to
20 days apart. Participants completed four trials of the 20-
meter walk test at each visit, which were equally divided
into two sessions (see Figure 1). Sessions were approxi-
mately ten minutes apart. Participants completed eight tri-
als during four sessions. The primary investigator (JM)
administered all walk tests using a standardized script and
protocol (see Appendix). All walk tests were conducted at
a self-selected pace.
Participants completed the 20-meter walk test in a 40-
meter long, unobstructed hallway. The primary inves-
tigator measured the 20-meter walk course with a
Redi-measure wheel (American Marking Corp, Omaha,
Nebraska) in the forward and reverse directions to en-
sure accuracy. Two 20 cm long strips of bright orange
tape were placed at the beginning and end of the course.
All participants wore comfortable, soft-soled shoes and
did not use walking aids. The primary investigator demon-
strated the walk test at a relaxed pace, exaggerating the in-
struction to pass the orange line by 3 to 4 steps. The
assessor then instructed the participants to place their toes
at the edge of the tape marking the beginning of the
course. Participants were prompted, “When I want you
to start, I will say ready, begin. Ready? Begin!” When the
participant began walking, the stopwatch was started,
and the assessor followed slightly behind and to the right
of the participant. The assessor stopped timing as soon
as the participant’s first heel completely crossed the strip
of orange tape. The assessor did not stop the time until
the participant’s entire foot completely crossed the far
edge of the tape. Participants had a 15 to 30 second
break between trials.
If the participant began to walk at a pace that was obvi-
ously not their normal self-selected walking speed as de-
termined by the assessor (e.g., running or jogging), the
test was immediately stopped. Participants were prompted
with a script to walk at a comfortable pace and told to
begin again (see Appendix).
Statistical analyses
Descriptive characteristics were calculated for participant
characteristics and walk times. Since previous research
typically only performs one or two walking trials, we cal-
culated the differences between walk times (raw and
average) as initial walk time minus follow-up walk time.
Therefore, negative differences represent a participant
who was slower during the follow-up observation and
positive differences characterize a participant with a faster
walking time during the follow-up observation.
Test-retest reliability between trials
We assessed differences between trials within each of the
four sessions to determine if trials were different within a
Figure 1 Walk test administration trials.
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not normally distributed, therefore, Wilcoxon signed-rank
tests were performed to assess the differences between 2
trials within session (significance was defined as p ≤ 0.01
to account for multiple comparisons). With a sample size
of 15 participants the Wilcoxon signed-rank tests could
detect a large difference (standardized effect size [d] =
1.00) between trials based on an alpha level of 0.01 and
power of 0.80 (calculated with G*Power 3.1.2). Spearman
correlations were performed to assess the relationship
between the 20-meter walk times between trials within
each session.Test-retest reliability between sessions
Five Wilcoxon signed-rank tests were performed to assess
the differences of the average 20-meter walk times be-
tween session 1 and the 3 subsequent sessions as well as
session 2 compared to the 2 subsequent sessions (signifi-
cance was defined as p ≤ 0.01 to account for multiple
comparisons). With a sample size of 15 participants the
Wilcoxon signed-rank tests could detect large differences
(standardized effect size [d] = 1.00) between sessions based
on an alpha level of 0.01 and power of 0.80 (calculated
with G*Power 3.1.2). Spearman correlations were per-
formed to assess the relationship between the average 20-
meter walk times across trials. Confidence intervals for
the Spearman correlations were calculated with PASS
11.0.10 (NCSS, LLC, Kaysville, Utah).Table 1 Participant characteristics (n = 15)
Variable Distribution
Female (%, n) 53% (8)
Caucasian (%, n) 67% (10)
Age (years; mean (sd)) 61.0 (7.8)
Body mass index (kg/m2; mean (sd)) 28.9 (5.4)
Kellgren-Lawrence Grade = 2 (%, n) 20% (3)
Kellgren-Lawrence Grade = 3 (%, n) 80% (12)
Day 1 WOMAC Pain Score (mean (sd)) 5.3 (1.3)
Day 2 WOMAC Pain Score (mean (sd)) 4.9 (2.0)Sensitivity: smallest detectable differences (SDD)
Data from the second sessions of both days (sessions 2
and 4) were used to determine the SDD in average 20-
meter walk times. The second session from each day
was selected because our data indicated that the first
session may not be valid and, therefore, should represent
practice trials. Since differences between session 2 and 4
were not normally distributed we calculated SDD based
on the median difference between sessions. To calculate
a more precise estimate of the SDD, we conducted 200
bootstrapped samples and determined the median of
each sample. We reported the SDD as the 2.5% and
97.5% percentiles from the empirical distribution of the
median from the boostrapped samples. All analyses were
performed in SAS 9.2 (Cary, NC), except when noted
otherwise.Results
Fifteen participants volunteered to perform 2 walking tri-
als without assistive devices during each of the 4 sessions
(average time between visit days = 13.9 days; range = 8 to
20 days), with 8 walking trials total. Participant character-
istics are described in Table 1. Patient-reported symptoms,
based on total WOMAC pain score, were not significantly
different between day 1 and day 2 (t(14) = 1.70, p = 0.11).
Between days, 5 participants had no change in WOMAC
pain score, 7 changed WOMAC pain scores by 1 unit, and
3 participants changed WOMAC pain score by 2 units.
The distribution of 20-meter walk times by trial is in
Figure 2.
Test-retest reliability between trials
Wilcoxon signed-rank tests between trials within the same
session demonstrated that trials in session 1 were signifi-
cantly different (p < 0.01) with a median difference of
0.78 seconds (− 0.06 m/s; Table 2). In the subsequent 3
sessions, the median differences between trials ranged
from −0.15 to 0.13 seconds (−0.01 to 0.02 m/s) and were
not significantly different (Table 2). Within sessions, trials
had good correlations (r ≥ 0.90).
Test-retest reliability between sessions
Differences and associations between sessions were evalu-
ated based on the average of two trials (Table 3). Based on
Wilcoxon signed-rank tests, walking times in session 1
were slower than session 2 (median difference = 0.53 sec-
onds, -0.04 m/s; Table 3). No other sessions were signi-
ficantly different (median differences ranging from −0.14
to 0.31 seconds, -0.03 to 0.01 m/s); however, we detected
a trend that participants walked slower in session 3
Figure 2 Distribution of 20 meter walk times (seconds) by trial (whiskers = interquartile range ± 1.5 times the interquartile range,
boxes = interquartile ranges, diamond = mean values, horizontal line in each box = median values). Lines under each set of trials indicate
trials performed during the same session.
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detected very strong associations between session 2 and
session 3 or 4 (Spearman r = 0.94 and 0.95). In contrast,
session 1 did not relate as well with sessions performed on
the second day (session 3 and 4; r = 0.78; p ≤ 0.01; for both
sessions after rounding).
Sensitivity: smallest detectable difference
Smallest detectable differences in average 20-meter walk
times were based on differences between session 2 and
session 4 (the second sessions of each day). The median
difference between sessions was −0.04 seconds (0.00 m/s).
Based on the empiric 95% confidence interval of the
bootstrapped medians, the SDD was change less than −
1.59 seconds (> 0.07 m/s; walking slower) or changeTable 2 Within-session comparisons and associations betwee
1st Trial 2nd Trial Medi
Median (25%, 75%) Median (25%, 75%)
(sec) (sec)
Day 1
Session 1 16.72 (15.38, 19.28) 15.53 (14.60, 18.18)
Session 2 15.28 (14.47, 18.12) 15.31 (14.32, 17.65)
Day 2
Session 3 15.71 (14.80, 17.94) 15.35 (14.37, 18.37)
Session 4 15.80 (14.41, 18.90) 15.44 (13.75, 19.66)
Note. P values are based on Wilcoxon signed-rank tests. 95% CI = 95% confidence igreater than 0.15 seconds (< −0.03 m/s; walking faster).
Based on this SDD, two participants walked slower in the
final session (Participant 1: average time = 18.44 seconds,
difference = −1.99 seconds; Participant 2: average time =
16.45 seconds, difference = −1.75 seconds) and one par-
ticipant walked faster (average time = 14.66 seconds, dif-
ference = 0.62 seconds). There was a potential systematic
bias of participants walking slower during the first and
second sessions on day 2 compared to the second session
of day 1 (10 [67%] participants walked slower in session 4
compared to session 2; based on differences below zero).
Discussion
Using a standardized protocol and one investigator to
eliminate variability introduced among raters, we found an trials
an difference Spearman Average of 2 trials
(sec) p
value
Correlation Median (25%, 75%)
(95% CI) (sec)
0.78 < 0.01 0.94 (0.83, 0.98) 16.11 (14.99, 19.07)
−0.15 0.63 0.90 (0.72, 0.97) 15.17 (14.85, 17.97)
0.05 0.55 0.97 (0.91, 0.99) 15.53 (14.78, 18.16)
0.13 0.98 0.98 (0.94, 0.99) 15.62 (14.16, 19.44)
nterval for Spearman Correlation Coefficient.
Table 3 Between-session comparisons and associations
Median
difference
95% CI of the Spearman correlation
Median* (95% CI)
Comparison (sec) p value (sec)
Session 1 – Session2 0.53 < 0.01 0.15, 0.91 0.88 (0.67, 0.96)
Session 1 – Session 3 0.31 0.22 −0.41, 0.71 0.78 (0.45, 0.92)
Session 1 – Session 4 0.12 0.28 −0.76, 1.33 0.78 (0.45, 0.92)
Session 2 – Session 3 −0.14 0.07 −1.13, 0.07 0.95 (0.85, 0.98)
Session 2 – Session 4 −0.04 0.19 −1.59, 0.15 0.94 (0.83, 0.98)
Note. P values are based on Wilcoxon signed-rank tests. 95% CI = 95% confidence interval. *Based on bootstrapping sample.
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the average times of session 1 and session 2. We detected
a trend that participants walked slower during session 3
compared to session 2. Our findings may indicate that
practice trials should be included when performing the
20-meter walk test. Greater session 1 and 3 walking times
as well as discrepancies between trials in the first session
may be due in part to a learning effect and by participants
acclimating to the test. Furthermore, the lack of correl-
ation between session 1 and the following sessions calls
into question the test-retest reliability of the first session
and thus the validity of walking times from that session.
Based on these findings we propose that clinicians who
use the 20-meter walk as a determinate of physical func-
tion change over time should conduct practice trials, aver-
age the results of two trials, and consider the potential for
a systematic bias at follow-up (i.e., walking slower).
Practice walks have been found to increase the test-
retest reliability of the 400-meter walk [28], but have not
been explored for the shorter walk tests. Despite the nu-
merous studies using the 20-meter walk as a physical
function outcome, none to our knowledge have reported
using practice trials. Participant acclimation to the test
may be vital to collecting a valid walk time [29,30], but,
to our knowledge, this has not been explicitly studied for
the 20-meter walk test. Session 3, despite being the first
session of day 2, was not significantly different from the
other sessions; however, there was a trend indicating that
participants walked slower in session 3 compared to ses-
sion 2. This suggests that to be cautious we should al-
ways consider using practice trials before administering
the walk tests.
Based on the SDD, we determined that change in 20-
meter walk times between −1.59 seconds (walking slower)
and 0.15 seconds (walking faster) should be considered
within the normal variation for the 20-meter walk test at
self-selected pace. Standardization of SDD among re-
searchers and clinicians will improve reporting and inter-
pretation of change outside of normal variability for
patients with knee OA. While the SDD describes the range
of normal variation it does not represent the amount of
change that may be clinically meaningful. Therefore, futureresearch may be warranted to determine how much
change in the 20-meter walk test at a self-selected pace
may be clinically meaningful to a patient (e.g., associated
with self-reported improvement or worsening of function).
While SDD is often considered to be evenly distributed
around zero change it is important to note that we identi-
fied a systematic bias that indicated participants are more
likely to walk slower in the final session than the second
session of day 2. If, however, we used the first session from
day 1, and did not include practice trials, we would find
an opposite bias (people walked faster in subsequent ses-
sion). This finding further highlights the potential import-
ance of practice trials when evaluating 20-meter walk
times. These potential biases should be considered when
evaluating if the 20-meter walk time improved or wors-
ened. Supporting the current SDD were our findings that
the three participants with differences in walk times out-
side of the SDD were also those who had changes in
symptoms, therefore their variation in walk time may be
real change.
While this study offers important insight into the 20-
meter walk test, one limitation of this study is that the
data may not be generalizable to other walking distances
that are occasionally performed (e.g., 6-minute walk test).
Another important limitation of this study may be our
small sample size. This may influence the generalizability
of these findings; however, they were representative of pa-
tients with mild to moderate knee OA that participate in
clinical trials in age and gender [31,32]. This is beneficial
since the 20-meter walk has a high test-re-test reliability
among patients with end-stage OA awaiting knee replace-
ments [33]. Our study along with previous research may
indicate that the 20-meter walk test is a robust assessment
of gait speed among patients with knee OA. Furthermore,
our sample size was similar to other reliability studies
[34-37] and was sufficient to demonstrate that trial 1 and
2 in the first session were statistically different and that
the correlations between the average walk time in session
1 and the other trials were smaller than the correlations
between session 2 and the subsequent sessions.
Another limitation of our study sample was that it in-
cluded only a few participants with slower walking
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potential limitations of the validity of this measure for
slower walkers (i.e., patients with greater functional im-
pairments). The slowest walkers had the biggest differ-
ences in walking times from Day 1 to Day 2. Future
research should further explore the reliability and sensi-
tivity of the 20-meter walk test among slower walkers.
Furthermore, it may be beneficial for future research to
explore potential sources of variation in walking times
(e.g., walking speed, assessor, time between visits, time
of assessment during the day) and how much they con-
tribute to variation in walking times.
Conclusions
In summary, our study demonstrated the first two walking
trials may not represent a participant’s normal self-paced
walking speed and lacked good test-retest reliability.
Therefore, practice trials are advised prior to a valid meas-
ure of a participant’s walk time and gait speed. We also
advocate that changes in 20-meter walk times at a self-
selected pace between −1.59 seconds (walking slower) and
0.15 seconds (walking faster) may represent normal vari-
ability in walking speed among those with mild to moder-
ate knee OA.
Appendix: 20-Meter Walk Test Protocol
Equipment:
 Stopwatch
 Bright colored tape
 25 meter long hallway
 Redi-measure wheel (in meters)
Setting up the course:
 Pick a stretch of hallway at least 25 meters in length.
Ideally, this area would not be highly travelled.
 Place one piece of tape on the ground. This will be
the starting line.
 Using the Redi-measure wheel, measure out a 20-
meter course down the hallway.
 Mark the other end with another piece of tape; this
will be the finish line.
 To ensure accuracy, re-measure the course in the
reverse direction.
Performing the test:
 The participant should be wearing comfortable, soft
soled shoes for this test. If the participant reports any significant discomfort,
or does not agree to participate in the explained
test, they should not be forced.
 Participants may use a cane or other walking aid to
walk the 20-meter course if they feel it is necessary.
However, keep in mind that many participants only
use their walking aids while outside of the home, so
do not assume they will need it just because they
brought an aid to the clinic.
 Read the participant the following script:Script 1
“Now I am going to observe how you normally walk. If you
use a cane or other walking aid, and you feel you need it to
walk a short distance, then you may use it. This is our
walking course. I want you to walk to the other end of the
course, at your usual speed, just as if you were to walk
down the street to go to the store. Walk 3 – 4 steps past the
other end of the tape before you stop. I will walk slightly
behind you. I will now demonstrate the walk to you”
 Demonstrate the walk. Do not walk at your normal
pace, rather, walk at a relaxed, leisurely pace all the
way past the other end of the course. Exaggerate
how far to walk by taking at least 3 or 4 steps past
the finish line.
 Return back at your normal speed.
 Ask the participant if they feel safe performing the
test, if so, assist them to the starting line.
 Be sure to get their toes as close as possible to the
edge of the course.
 The examiner should only have a stopwatch. Read
the following to the participant:
“When I want you to start, I will say ready, begin.
Ready? Begin!”
 Press the start/stop button on the stopwatch as
soon as the participant starts to move across the
starting line.
 Follow the participant all the way down to the other
end of the course. The examiner should be postioned
slightly behind and to the side of the participant,
keeping a close eye on the participant’s feet.
 The test is over when the participants first foot
completely crosses the line. If the participant’s foot
lands on the line, do not stop the timer until one
heel completely crosses the finish line.
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other end of the course and record the walking
time. If they require a chair, provide one.
 NOTE: If the participant begins the test and is
obviously not walking at their normal pace (e.g.
running or jogging please read the following to the
participant: “Please stop the test. Is this how you
normally walk down the street going to the store? If
so we will begin again. If not, please remember to
walk at your normal walking pace.” and then have
participant start the test again.
 After recording the walk information, read the
following script to the participant:
Repeating the Walk Test
“Now I want you to repeat the walk. Remember to walk
at your usual pace and walk all the way past the other
end of the course before you stop. I will be walking with
you.”
 If the participant feels safe performing the test,
assist them to the starting line.
 Be sure to get their toes as close as possible to the
edge of the course.
 The examiner should only have a stopwatch.
 Read the following to the participant:
“When I want you to start, I will say ‘Ready? Begin!’
Ready? Begin!”
 Press the start/stop button on the stopwatch as
soon as the participant starts to move across the
starting line.
 Follow the participant all the way down to the other
end of the course. The examiner should be positioned
slightly behind and to the side of the participant,
keeping a close eye on the participant’s feet.
 The test is over when the participant’s first foot
completely crosses the line. If the participant’s foot
lands on the line, do not stop the timer until one
heel completely crosses the finish line.
Repeat the walk test two more times. Assist the par-
ticipant to their seat and record all information.
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